GCG and Obesity: Notably, recent data showed that glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide, as well as dual gastric inhibitory peptides (GIP) and GLP-1 receptor agonist, such as tirzepatide, are effective treatment of obesity and probably reduce the risk of cardiovascular events in obese or diabetic patients (111, 146–148).